20/20 Biolabs Inc.
20/20 Biolabs Inc.
Your view on AIDX
Overview
What the company does, where it operates, and who runs it.
About 20/20 Biolabs Inc.
- Industry
- Medical - Care Facilities
- Sector
- Healthcare
- CEO
- Jonathan Cohen
- Headquarters
- 15810 Gaither Road, Gaithersburg, MD, US
- Industry
- Medical - Care Facilities
- Sector
- Healthcare
- CEO
- Jonathan Cohen
- Headquarters
- 15810 Gaither Road, Gaithersburg, MD, US
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test.
It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market.
The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for 20/20 Biolabs Inc., and the rating behind it. AIDX last traded at $0.34; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for 20/20 Biolabs Inc.. Starting points for 20/20 Biolabs Inc.: EPS -$0.54, beta 1.54 — an Medical - Care Facilities name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for 20/20 Biolabs Inc.. 20/20 Biolabs Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for 20/20 Biolabs Inc.. Trailing twelve-month EPS for 20/20 Biolabs Inc. stands at -$0.54. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for 20/20 Biolabs Inc.. 20/20 Biolabs Inc. has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
20/20 Biolabs Inc. valued side by side against its closest peers. 20/20 Biolabs Inc. is measured against Medical - Care Facilities peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold 20/20 Biolabs Inc., and how their positions are changing. At a $4.2M market value, institutional positions materially move 20/20 Biolabs Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by 20/20 Biolabs Inc. executives and directors. Shares of 20/20 Biolabs Inc. have traded between $0.40 and $50.00 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming 20/20 Biolabs Inc.. 20/20 Biolabs Inc. is a $4.2M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming 20/20 Biolabs Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for 20/20 Biolabs Inc.. Coverage tracks 20/20 Biolabs Inc. within Medical - Care Facilities (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.